P1617: A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A

ABSTRACT:

SUBMITTER: Xue F 

PROVIDER: S-EPMC10430368 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature